Bridging Discovery And CMC With Rapid Pools

Complex antibody formats like bispecifics and multispecifics often show promising results in transient expression screening, only to reveal manufacturability issues during cell line development. Join us as we examine how early-stage stable CHO expression data can bridge the gap between discovery and CMC, helping teams make better-informed decisions about which molecular designs to advance.

Through two detailed case studies, we'll show how stable pool screening changed lead selection by revealing performance differences invisible in transient systems, and how targeted redesign rescued a challenging molecule that might otherwise have been abandoned. Learn practical approaches to integrate manufacturability assessments earlier in your protein engineering workflow.